Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in Catalyst Pharmaceuticals, Inc. $CPRX

Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 52,156 shares of the biopharmaceutical company’s stock, valued at approximately $1,027,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CPRX. Huntington National Bank grew its holdings in Catalyst Pharmaceuticals by 105.0% during the 2nd quarter. Huntington National Bank now owns 1,433 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 734 shares during the last quarter. Rothschild Investment LLC boosted its stake in shares of Catalyst Pharmaceuticals by 1,085.7% during the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,520 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 331.4% during the third quarter. Bessemer Group Inc. now owns 3,486 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 2,678 shares in the last quarter. Dakota Community Bank & Trust NA purchased a new stake in shares of Catalyst Pharmaceuticals during the second quarter worth about $81,000. Finally, Jones Financial Companies Lllp raised its position in shares of Catalyst Pharmaceuticals by 14.0% in the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock valued at $79,000 after buying an additional 498 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $24.30 on Monday. The stock has a market cap of $2.99 billion, a price-to-earnings ratio of 14.13, a price-to-earnings-growth ratio of 0.81 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $26.58. The business’s 50-day simple moving average is $23.83 and its 200 day simple moving average is $22.08.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Carmen Jeffrey Del sold 10,983 shares of the stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $23.33, for a total transaction of $256,233.39. Following the completion of the transaction, the insider directly owned 3,962 shares in the company, valued at approximately $92,433.46. This represents a 73.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Molly Harper sold 26,746 shares of Catalyst Pharmaceuticals stock in a transaction on Friday, December 12th. The stock was sold at an average price of $23.25, for a total transaction of $621,844.50. Following the completion of the sale, the director owned 2,360 shares of the company’s stock, valued at approximately $54,870. This trade represents a 91.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 10.40% of the company’s stock.

Analyst Upgrades and Downgrades

CPRX has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Monday, December 29th. Oppenheimer reissued an “outperform” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 7th. Finally, Citigroup upped their price target on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $33.20.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).